MCID: NRV007
MIFTS: 73

Nervous System Disease

Categories: Neuronal diseases, Immune diseases

Aliases & Classifications for Nervous System Disease

MalaCards integrated aliases for Nervous System Disease:

Name: Nervous System Disease 12 15
Abnormality of the Nervous System 29 6
Nervous System Diseases 44
Nervous System Disorder 73

Classifications:



External Ids:

Disease Ontology 12 DOID:863
ICD9CM 35 349.9
MeSH 44 D009422
NCIt 50 C26835
UMLS 73 C0027765

Summaries for Nervous System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in the central nervous system or located in the peripheral nervous system.

MalaCards based summary : Nervous System Disease, also known as abnormality of the nervous system, is related to peripheral nervous system disease and central nervous system disease, and has symptoms including aphonia, ataxia and athetosis. An important gene associated with Nervous System Disease is ENSG00000179253 (
In human nervous system,BC200 RNA is expressed by a subpopulation of neurons analogous to BC1 RNA,a 152 nt noncoding RNA localized in the dendrite-rich neuropil areas [147].
Dysfunction Pattern: ), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Zinc and Naproxen have been mentioned in the context of this disorder. Affiliated tissues include the central nervous system or, brain and spinal cord, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 76 Nervous system diseases, also known as nervous system or neurological disorders, refers to a small class... more...

Related Diseases for Nervous System Disease

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease

Diseases related to Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 525)
# Related Disease Score Top Affiliating Genes
1 peripheral nervous system disease 35.4 MFRP TRPV1 TUBB3
2 central nervous system disease 35.1 APP BACE1 CCR1 CXCR3 GC IFNG
3 meningitis 33.6 IFNG IL1B IL6 TLR9 TNF
4 multiple sclerosis 33.4 CCR1 CXCR3 IFNG IL1B IL6 MOG
5 meningoencephalitis 33.0 APP IL6 TLR9
6 toxic encephalopathy 33.0 APP BACE1 IL1B TRPV1
7 pneumonia 31.9 IL1B IL6 TLR9 TNF
8 hematopoietic stem cell transplantation 31.8 IFNG IL6 TNF
9 arthritis 31.7 CSF2 IFNG IL1B IL6 TNF
10 acquired immunodeficiency syndrome 31.7 CSF2 IFNG IL1B IL6 TNF
11 central nervous system vasculitis 31.5 IL1B IL6 TLR9 TNF
12 chlamydia 31.4 IFNG IL1B IL6 NOS2 TNF
13 toxoplasmosis 31.4 IFNG IL1B IL6 TLR9 TNF
14 colitis 31.3 IFNG IL1B IL6 NOS2 TLR9 TNF
15 mouth disease 31.3 IFNG IL1B IL6 TLR9 TNF TRPV1
16 esophagitis 31.3 IL1B IL6 TRPV1
17 inflammatory bowel disease 31.2 IFNG IL1B IL6 NOS2 TLR9 TNF
18 autonomic nervous system disease 12.2
19 staphylococcal toxic shock syndrome 11.5 IFNG IL1B TNF
20 autoimmune myocarditis 11.5 IFNG IL1B TNF
21 laryngitis 11.5 IL1B IL6 TNF
22 trichosporonosis 11.5 CSF2 IFNG TNF
23 acute vascular insufficiency of intestine 11.5 IL1B IL6 TNF
24 burns 11.5 CSF2 IL1B TNF
25 poems syndrome 11.5 IL1B IL6 TNF
26 osteosclerotic myeloma 11.5 IL1B IL6 TNF
27 stachybotrys chartarum 11.5 IL1B IL6 TNF
28 intermediate uveitis 11.5 CXCR3 IFNG IL6 TNF
29 microscopic colitis 11.5 IFNG IL6 TNF
30 foix-alajouanine syndrome 11.5
31 orofacial granulomatosis 11.5 CXCR3 IFNG TNF
32 myelitis 11.5 IL6 MOG TNF
33 crohn's colitis 11.5 IFNG IL1B NOS2 TNF
34 meconium aspiration syndrome 11.5 CSF2 IFNG IL6 TNF
35 neuritis 11.5 IFNG IL1B MOG TNF
36 erythema multiforme 11.5 CXCR3 IFNG TNF
37 cytomegalovirus retinitis 11.5 CSF2 IFNG TNF
38 hemorrhagic fever 11.5 IFNG IL6 TNF
39 typhoid fever 11.5 IFNG IL1B IL6 TNF
40 allergic contact dermatitis 11.4 CXCR3 IFNG IL1B TNF
41 endometritis 11.4 IL1B IL6 TNF
42 bronchiolitis obliterans 11.4 CXCR3 IFNG IL6 TNF
43 lymphadenitis 11.4 CXCR3 IFNG IL1B TNF
44 aseptic meningitis 11.4 IFNG IL1B TNF
45 pulmonary sarcoidosis 11.4 CSF2 CXCR3 IFNG TNF
46 joint disorders 11.4 IL1B IL6 TNF
47 cytomegalovirus infection 11.4 IFNG IL6 TNF
48 proliferative glomerulonephritis 11.4 CXCR3 IFNG IL6
49 gastroenteritis 11.4 IFNG IL1B IL6 TNF
50 commensal bacterial infectious disease 11.4 IL1B IL6 TNF

Comorbidity relations with Nervous System Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Nervous System Disease:



Diseases related to Nervous System Disease

Symptoms & Phenotypes for Nervous System Disease

UMLS symptoms related to Nervous System Disease:


aphonia, ataxia, athetosis, back pain, cerebellar ataxia, cheyne-stokes respiration, dizziness, muscular fasciculation, headache, hemiparesis, hemiplegia, hoarseness, hyperalgesia, hyperesthesia, leg cramps, meningism, flaccid muscle tone, muscle rigidity, muscle spasticity, myoclonus, neuralgia, numbness, ophthalmoplegia, pain, reflex, abnormal, sciatica, seizures, spasm, pathological conditions, signs and symptoms, syncope, torticollis, tremor, vertigo, flaccid paralysis, burning sensation, hypalgesia, agitation, lassitude, chronic pain, scalp tenderness, cogwheel rigidity, opisthotonus, circumoral paresthesia, spasmodic torticollis, lightheadedness, muscular stiffness, musculoskeletal symptom, muscular incoordination, muscle fibrillation, asterixis, bradykinesia, micropsia, clumsiness, asynergia, adiadochokinesis, fine tremor, coarse tremor, action tremor, epileptic aura, lid retraction, spasm oropharyngeal, astasia, dysdiadochokinesis, fumbling, head discomfort, head pressure, head tightness, hypersensation skin, bulging fontanelle, numbness localized, neurologic symptoms, paresthesia, distal, paresthesia mucosal, paresthesia skin, tingling of skin, skeletal muscle paralysis, paralysis muscle general skeletal, paralysis muscle local skeletal, paralysis lower motor neuron type, scotoma, scintillating, tongue sluggish, tremor, perioral, tremor, limb, tremor, muscle, nerve tremors, dyskinesia neonatal, tremor, neonatal, absence attacks, anesthesia mouth, anesthesia lip, anesthesia oral mucosa, anesthesia tongue, burning sensation of skin, post-lumbar puncture headache, tonic seizures, extreme exhaustion, agitation mental, akathisia, dysesthesia, rigor - temperature-associated observation, involuntary movements, vertigo/dizziness, burning mucosal, paresthesia mouth, numb mouth, eyes rolling, electric shock sensation, jaw stiffness, equilibration disorder, muzzy headed, clouded consciousness, motor restlessness, decreased tendon reflex, myotonus (finding), reaction to spinal or lumbar puncture, staggering gait, non-epileptic convulsion, gait ataxia, headache fullness, sleeplessness, symptoms, constitutional symptom

MGI Mouse Phenotypes related to Nervous System Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 MOG NOS2 TRPV1 PROM1 IL6 TLR9
2 homeostasis/metabolism MP:0005376 10.25 TNF NOS2 IL1B TLR9 IL6 CCR1
3 cardiovascular system MP:0005385 10.24 TNF NOS2 PROM1 IL6 IFNG CSF2
4 hematopoietic system MP:0005397 10.2 MOG TNF NOS2 IL1B TLR9 IL6
5 immune system MP:0005387 10.18 TNF MOG NOS2 IL1B IL6 TLR9
6 mortality/aging MP:0010768 10.13 TNF NOS2 IL1B PROM1 TLR9 IL6
7 integument MP:0010771 10.02 TNF NOS2 IL1B IL6 IFNG CSF2
8 nervous system MP:0003631 9.97 MFRP TNF MOG NOS2 TRPV1 PROM1
9 neoplasm MP:0002006 9.91 TNF NOS2 TRPV1 PROM1 IL6 CSF2
10 renal/urinary system MP:0005367 9.56 NOS2 IL6 TLR9 CCR1 IFNG CSF2
11 respiratory system MP:0005388 9.23 TNF NOS2 IL6 CCR1 IFNG CSF2

Drugs & Therapeutics for Nervous System Disease

Drugs for Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1367)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 23994
2
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22204-53-1 1302 156391
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
4
Etomidate Approved Phase 4,Phase 3 33125-97-2 36339 667484
5
rituximab Approved Phase 4,Phase 2,Phase 1 174722-31-7 10201696
6
Ranibizumab Approved Phase 4,Phase 2,Phase 1 347396-82-1 459903
7
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79617-96-2 68617
8
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2216-51-5 16666
9
Nicotine Approved Phase 4,Phase 2,Not Applicable 54-11-5 942 89594
10
Remifentanil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132875-61-7 60815
11
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79902-63-9 54454
12
Metformin Approved Phase 4,Phase 3,Not Applicable 657-24-9 14219 4091
13
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 1744-22-5 5070
14
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
15
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
16
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
17
Rivastigmine Approved, Investigational Phase 4,Phase 1 123441-03-2 77991
18
Imipramine Approved Phase 4,Phase 3 50-49-7 3696
19
Cysteamine Approved, Investigational Phase 4,Not Applicable 60-23-1 6058
20
Etoricoxib Approved, Investigational Phase 4,Phase 3 202409-33-4 123619
21
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
22
Clobazam Approved, Illicit Phase 4,Phase 3 22316-47-8 2789
23
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
24
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
25
Aprepitant Approved, Investigational Phase 4,Early Phase 1 170729-80-3 151165 6918365
26
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69-65-8 453 6251
27
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
28
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 74103-06-3, 66635-83-4 3826
29
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 73590-58-6 4594
30
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
31
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 10118-90-8 5281021
32
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
33
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 97240-79-4 5284627
34
Timolol Approved Phase 4,Phase 2,Phase 1,Not Applicable 26839-75-8 33624 5478
35
Hydrocodone Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 125-29-1 5284569
36
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
37
Atracurium Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 64228-79-1 47319
38
Galantamine Approved Phase 4,Phase 3 357-70-0 9651
39
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 27203-92-5 33741
40
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
41
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 57-41-0 1775
42
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85622-93-1 5394
43 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
44
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-46-4 2554
45
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 15307-86-5 3033
46
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6740-88-1 3821
47
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
48
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
49
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
50
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 68291-97-4 5734

Interventional clinical trials:

(show top 50) (show all 10246)
# Name Status NCT ID Phase Drugs
1 Normal Oxygenation Versus Hyperoxia in the Intensive Care Unit (ICU) Unknown status NCT01319643 Phase 4 Oxygen
2 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
3 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
4 How Many Patients Are in Need of Vitamin B12 Injections? Unknown status NCT00326833 Phase 4 vitamin B12
5 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
6 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
7 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
8 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4 Ranibizumab
9 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
10 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
11 ShuntCheck-Micro-Pumper Pediatric Clinical Outcomes Study Unknown status NCT01881711 Phase 4
12 Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy Unknown status NCT01052337 Phase 4 anaesthetics: sevofluorane
13 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
14 Determination of the Minimum Local Analgesic Dose of Spinal Chloroprocaine in Labour Unknown status NCT01909089 Phase 4 Spinal administration of chloroprocaine.
15 Oxepa in Multiple Trauma Unknown status NCT01099501 Phase 4
16 Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy Unknown status NCT02726919 Phase 4 Clobazam
17 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
18 A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy Unknown status NCT01875562 Phase 4 Qishe Pill
19 NIMIP: Non Invasive Measurement of the Intracranial Pressure Unknown status NCT01685450 Phase 4
20 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
21 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
22 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
23 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
24 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
25 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
26 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
27 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
28 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
29 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
30 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
31 Sleep Disturbances in Hospitalized Children Unknown status NCT00749814 Phase 4
32 Morphine Versus Ketorolac in Low Back Pain Unknown status NCT02782286 Phase 4 Ketorolac;Morphine
33 Dexamethasone in Pain Control After Total Knee Replacement Unknown status NCT02767882 Phase 4 Dexamethasone;Saline
34 Intraoperative Ketamine on Chronic Pain After Mastectomy Unknown status NCT02729805 Phase 4 Saline;Ketamine 0.5mg/kg;Ketamine 0.75mg/kg
35 Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain Unknown status NCT02699281 Phase 4 ultra-micronized palmitoylethanolamide;Placebo
36 Study to Examine Pain Relief With Supplemental Intrathecal Morphine in TKA Patients Unknown status NCT02620631 Phase 4 Morphine;Placebo
37 Comparison of Ketoprofen Gel to Placebo in Mechanical Low Back Pain Unknown status NCT02619695 Phase 4 Fastjel
38 Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty Unknown status NCT02603900 Phase 4 ropivacaine;bupivacaine
39 Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus Unknown status NCT02518789 Phase 4 Low-dose Dexmedetomidine;High-dose dexmedetomidine;normal saline;Etomidate;midazolam,fentanyl,rocuronium;propofol,remifentanil,cis atracurium
40 A Trial Comparing Adductor Canal Catheter and Intraarticular Catheter Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
41 Birth Ball Versus Meperidine and Haloperidol Injection for Pain Relief During First Stage of Labour Unknown status NCT02493192 Phase 4 pethidine and haloperidol injection
42 Ketoprofen Gel vs Placebo in Low Back Pain Unknown status NCT02491879 Phase 4 Ketoprofen
43 The Effect of no Muscle Relaxant Versus Reduced-dose Rocuronium on Anesthesia in Adenotonsillectomy Unknown status NCT02467595 Phase 4 Rocuronium bromide 0.15 mg kg-1;Rocuronium bromide 0.3 mg kg-1;Fentanyl;Propofol;Sevoflurane
44 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
45 Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit Unknown status NCT02198404 Phase 4 sedation with propofol
46 The Effect of Ketamine Infusion on Lumbar Surgery Unknown status NCT02154438 Phase 4 Ketamine
47 Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia Unknown status NCT02141737 Phase 4 Lidocaine Hydrochloride Injection;Etomidate Fat Emulsion Injection;normal saline;Midazolam Injection;Fentanyl Citrate Injection;Rocuronium Injection
48 Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain Unknown status NCT02125968 Phase 4
49 Effect of Three Therapeutics Strategies on Patients With a Chronic Back Pain (PLURICLEF). Unknown status NCT02030171 Phase 4
50 Therapeutic Effects of Monochromatic Infrared Energy Therapy on Patients With Chronic Low Back Pain Unknown status NCT01920971 Phase 4

Search NIH Clinical Center for Nervous System Disease

Cochrane evidence based reviews: nervous system diseases

Genetic Tests for Nervous System Disease

Genetic tests related to Nervous System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Nervous System 29

Anatomical Context for Nervous System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Disease:

19
The Central Nervous System Or

MalaCards organs/tissues related to Nervous System Disease:

41
Brain, Spinal Cord, Testes, Bone, Heart, Eye, Cortex

Publications for Nervous System Disease

Articles related to Nervous System Disease:

(show top 50) (show all 370)
# Title Authors Year
1
Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy. ( 29332716 )
2018
2
Nervous system disease in Systemic Lupus Erythematosus: Current status and future directions. ( 29927108 )
2018
3
AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease). ( 29316812 )
2018
4
Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up. ( 29515419 )
2018
5
A matrix metalloproteinase 9 (MMP9) gene single nucleotide polymorphism is associated with predisposition to tick-borne encephalitis virus-induced severe central nervous system disease. ( 29496490 )
2018
6
Stem cells in the treatment of central nervous system disease. ( 29523970 )
2018
7
Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii. ( 28933846 )
2017
8
Occupational exposure to extremely low-frequency magnetic fields and risk for central nervous system disease: an update of a Danish cohort study among utility workers. ( 28429106 )
2017
9
Is the Eye an Extension of the Brain in Central Nervous System Disease? ( 28609158 )
2017
10
Central Nervous System Disease in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis. ( 29061243 )
2017
11
Central nervous system disease in pediatric acute myeloid leukemia. ( 28853216 )
2017
12
Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. ( 29103429 )
2017
13
Metabolic Profiling of Central Nervous System Disease in Trypanosoma brucei rhodesiense infection. ( 28927234 )
2017
14
Production of transgenic pigs using the<i>pGFAP-CreER<sup>T2</sup>;EGFP<sup>LoxP</sup></i>inducible system for central nervous system disease models. ( 29284207 )
2017
15
Mesencephalic astrocyte-derived neurotrophic factor and its role in nervous system disease. ( 28685189 )
2017
16
Central Nervous System Disease, Education, and Race Impact Radiation Refusal in Pediatric Cancer Patients. ( 28538508 )
2017
17
Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. ( 28453910 )
2017
18
Cerebrospinal fluid pleocytosis in infectious and noninfectious central nervous system disease: A retrospective cohort study. ( 28471963 )
2017
19
Wasp Venom Immunotherapy in a Patient With Immune-Mediated Inflammatory Central Nervous System Disease: Is it Safe? ( 28398199 )
2017
20
Editorial: Induction of Central Nervous System Disease by the Adaptive Immune Response. ( 29038655 )
2017
21
The function of NOD-like receptors in central nervous system diseases. ( 28029680 )
2017
22
Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening. ( 28075486 )
2017
23
Gpr124 is essential for blood-brain barrier integrity in central nervous system disease. ( 28288111 )
2017
24
Central nervous system disease and genital disease in harbor porpoises (Phocoena phocoena) are associated with different herpesviruses. ( 26861818 )
2016
25
Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia. ( 26997880 )
2016
26
Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease. ( 26831951 )
2016
27
Clinical, electrophysiological, and biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe'sA disease). ( 27638585 )
2016
28
Glial biomarkers in human central nervous system disease. ( 27228454 )
2016
29
Association of Resident Duty Hour Restrictions on Mortality of Nervous System Disease and Disorder. ( 27777670 )
2016
30
Delivery of an adeno-associated virus vector into CSF attenuates central nervous system disease in mucopolysaccharidosis type II mice. ( 27510804 )
2016
31
The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability. ( 27133811 )
2016
32
AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage-Th17 Axis. ( 27354217 )
2016
33
Hodgkin Lymphoma With Central Nervous System Disease at Primary Presentation. ( 26814676 )
2016
34
Raccoon Roundworm Infection Associated with Central Nervous System Disease and Ocular Disease - Six States, 2013-2015. ( 27608169 )
2016
35
An In Vivo Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System Disease. ( 26843629 )
2016
36
Clinical and Laboratory Findings That Differentiate Herpes Simplex Virus Central Nervous System Disease from Enteroviral Meningitis. ( 27563314 )
2016
37
Central nervous system disease in childhood acute lymphoblastic leukaemia- a review. ( 26990196 )
2016
38
Macaque species susceptibility to simian immunodeficiency virus: increased incidence of SIV central nervous system disease in pigtailed macaques versus rhesus macaques. ( 25672885 )
2015
39
Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. ( 26447927 )
2015
40
Targeted Temperature Management in Pediatric Central Nervous System Disease. ( 26042193 )
2015
41
Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease. ( 25474439 )
2015
42
Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. ( 25641427 )
2015
43
Intranasal delivery of stem cells as therapy for central nervous system disease. ( 25645932 )
2015
44
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here? ( 26314739 )
2015
45
Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System Disease. ( 26793168 )
2015
46
Diagnostic value of aquaporin 4 antibody in assessing idiopathic inflammatory demyelinating central nervous system diseases in Egyptian patients. ( 25677878 )
2015
47
Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy: Case report. ( 26390826 )
2015
48
Conjunctival biopsy to diagnose neurosarcoidosis in patients with inflammatory nervous system disease of unknown etiology. ( 29443212 )
2015
49
A coumarin-based fluorescent probe as a central nervous system disease biomarker. ( 25390405 )
2014
50
Evaluation of malnutrition in patients with nervous system disease. ( 25192880 )
2014

Variations for Nervous System Disease

ClinVar genetic disease variations for Nervous System Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;X;t(Y;3)(p11.2;p12.3)dn Translocation Likely pathogenic
2 46;XY;t(1;3)(q32.3;q21.1) Translocation Uncertain significance

Expression for Nervous System Disease

Search GEO for disease gene expression data for Nervous System Disease.

Pathways for Nervous System Disease

Pathways related to Nervous System Disease according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 CCR1 CSF2 IFNG IL1B IL6 NOS2
2
Show member pathways
13.3 CCR1 CSF2 CXCR3 IL1B IL6 TNF
3
Show member pathways
13.01 IFNG IL1B IL6 NOS2 TLR9 TNF
4
Show member pathways
12.78 IFNG IL1B IL6 TLR9 TNF
5
Show member pathways
12.76 APP IFNG IL1B IL6 TNF
6
Show member pathways
12.64 CSF2 IFNG IL1B IL6 TNF
7
Show member pathways
12.59 IFNG IL1B IL6 NOS2 TNF
8
Show member pathways
12.43 IFNG IL1B IL6 TNF
9
Show member pathways
12.43 CSF2 IFNG IL1B IL6 TNF
10
Show member pathways
12.34 CSF2 IFNG IL1B IL6 TNF
11
Show member pathways
12.32 IFNG IL1B IL6 TNF
12
Show member pathways
12.28 IFNG IL1B IL6 NOS2 TNF
13
Show member pathways
12.26 IFNG IL1B IL6 TLR9 TNF
14
Show member pathways
12.25 IFNG IL1B NOS2 TNF
15
Show member pathways
12.22 IL1B IL6 NOS2 TNF
16
Show member pathways
12.21 IL1B IL6 TLR9 TNF
17 12.19 IFNG IL1B IL6 NOS2 TLR9 TNF
18 12.18 IFNG IL6 NOS2 TLR9 TNF
19
Show member pathways
12.13 IFNG IL1B IL6 NOS2 TLR9 TNF
20 12.01 IFNG IL1B IL6 NOS2 TNF
21 11.99 IL1B IL6 NOS2 TNF
22 11.99 CCR1 CSF2 IFNG IL6 TNF
23 11.96 CSF2 IL1B IL6 TNF
24 11.9 CSF2 IL1B IL6 TNF
25 11.85 CSF2 IFNG IL1B IL6 TNF
26 11.81 CXCR3 IFNG IL1B TNF
27 11.81 CSF2 IFNG IL1B IL6 NOS2
28 11.79 CSF2 IFNG IL6
29 11.78 IL1B IL6 NOS2 TNF
30 11.78 CSF2 IFNG IL1B IL6 NOS2 TNF
31
Show member pathways
11.75 CSF2 IFNG TNF
32 11.68 CSF2 IL1B IL6 TNF
33 11.6 IFNG IL6 NOS2
34 11.59 IL1B IL6 TNF
35 11.55 IFNG IL6 TNF
36 11.54 IFNG IL1B NOS2 TNF
37 11.52 IFNG IL1B TNF
38 11.52 CSF2 IL1B IL6
39 11.5 IFNG IL1B IL6 TNF
40 11.49 CCR1 CSF2 IL1B IL6 TNF
41 11.46 IFNG IL1B IL6 TLR9 TNF
42 11.39 IFNG IL1B NOS2
43 11.36 IL1B IL6 TNF
44 11.32 IFNG IL1B IL6 TNF
45 11.31